Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.0.50 CHF
Change Today 0.00 / 0.00%
Volume 318.9K
As of 11:43 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

cytos biotechnology ag-reg (CYTN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/15 - SFr.2.60
52 Week Low
10/7/14 - SFr.0.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cytos biotechnology ag-reg (CYTN) Related Businessweek News

No Related Businessweek News Found

cytos biotechnology ag-reg (CYTN) Details

Cytos Biotechnology AG focuses on the development and commercialization of biopharmaceutical products for use in the treatment and prevention of chronic diseases. The company has collaborative research, option, and license agreement with Novartis for the development of CAD106, an active immunotherapy for the treatment of patients with Alzheimer’s disease; license agreement with Pfizer Inc. for developing an anti-IgE vaccine; and collaborative research, development, and commercialization agreement with Singapore’s Agency for Science, Technology and Research. Cytos Biotechnology AG is based in Schlieren, Switzerland.

cytos biotechnology ag-reg (CYTN) Top Compensated Officers

Chairman, Chief Executive Officer, Member of ...
Total Annual Compensation: SFr.546.0K
Compensation as of Fiscal Year 2014.

cytos biotechnology ag-reg (CYTN) Key Developments

Cytos Biotechnology AG, Annual General Meeting, Jun 29, 2015

Cytos Biotechnology AG, Annual General Meeting, Jun 29, 2015., at 11:00 Central European Standard Time. Location: Schlieren.

Cytos Biotechnology AG Reports Earnings Results for the Full Year of 2014

Cytos Biotechnology AG reported earnings results for the full year of 2014. For the period, the company reported revenue of CHF 1.0 million compared to CHF 1.0 million a year ago. Operating loss was CHF 18.9 million compared to CHF 24.3 million a year ago. Net loss was CHF 34.0 million compared to CHF 30.8 million a year ago. Net loss per share was CHF 1.11 compared to CHF 1.32 a year ago.

Cytos Biotechnology AG Auditor Raises 'Going Concern' Doubt

Cytos Biotechnology AG filed its Annual on Apr 28, 2015 for the period ending Dec 31, 2014. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTN:SW SFr.0.50 CHF 0.00

CYTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTN.
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOS BIOTECHNOLOGY AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at